
(ACX)
Across Protocol (ACX) price prediction for 2026-2030Listed
How has Across Protocol (ACX) performed this year? What are the short-term outlooks (1 week, 1 month, 3 months) and the long-term forecast for 2026-2030? We analyze and forecast ACX's future price based on recent trends, historical data, and technical indicators such as Moving Averages (MA), RSI, and MACD. You can also use our price prediction tool to estimate potential returns by setting your target growth rate.
Across Protocol (ACX) price
Last updated: Aug 19, 2026, 23:35:02
24h high
0.041300 USD
Market cap
28.82M USD
24h low
0.040930 USD
24h volume
746.14K USD
Across Protocol (ACX) price
0.04013 USD
Date
--
Enter your expected growth for Across Protocol to calculate its future value
Current price
0.04013 USD
Momentum
Bullish
14D RSI
42.33
50D SMA
0.04129 USD
200W SMA
0.041106 USD
Fear & Greed
55
1. Weekly EMA 200
The weekly EMA 200 is a widely used bull/bear market divider and long-term trend line in crypto.
2. Daily EMA 50
3. MACD trend & reversal signals
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.